Compounding Panel Backs Peptides for the 503A Bulks List, Against FDA Reviewers’ Recommendations

Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Marevgenna - stock.adobe.com.Updated 7/27 with ISMP and ECRI statementBy G